TRIKAFTA Vertex Pharmaceuticals Australia Pty Ltd
Product name
TRIKAFTA
Accepted date
Apr-2024
Active ingredients
elexacaftor, ivacaftor, tezacaftor
Proposed indication
Trikafta is indicated for the treatment of cystic fibrosis in patients with responsive gene mutations.
Application type
C (new indication)
Publication date
Apr-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.